Advertisement
Singapore markets open in 6 hours 8 minutes

  • Straits Times Index

    3,289.42
    -23.93 (-0.72%)
     

  • S&P 500

    5,300.44
    +53.76 (+1.02%)
     

  • Dow

    39,833.86
    +275.75 (+0.70%)
     

  • Nasdaq

    16,728.56
    +217.38 (+1.32%)
     

  • Bitcoin USD

    65,413.18
    +4,053.55 (+6.61%)
     

  • CMC Crypto 200

    1,380.70
    +112.75 (+8.89%)
     

  • FTSE 100

    8,445.80
    +17.67 (+0.21%)
     

  • Gold

    2,390.50
    +30.60 (+1.30%)
     

  • Crude Oil

    78.74
    +0.72 (+0.92%)
     

  • 10-Yr Bond

    4.3580
    -0.0870 (-1.96%)
     

  • Nikkei

    38,385.73
    +29.67 (+0.08%)
     

  • Hang Seng

    19,073.71
    -41.35 (-0.22%)
     

  • FTSE Bursa Malaysia

    1,603.23
    -2.65 (-0.17%)
     

  • Jakarta Composite Index

    7,179.83
    +96.07 (+1.36%)
     

  • PSE Index

    6,558.63
    -49.73 (-0.75%)
     

Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rain Therapeutics Inc
·1-min read

NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Additional details can be found below:

Date: Monday, September 13, 2021
Time: 7:00 a.m. ET
Location: Webcast Link – or on the Rain website (click here)

A replay of the presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

ADVERTISEMENT

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com